Table 1.

Summary of findings on the effect of neonatal antigen administration on subsequent AAD development

n	Birth	4 weeks	6 weeks	AAD
4	—	—	Aerosol	No
9	—	OVA/alum i.p.	Aerosol	Yes
6	OVA (1 mg)	Aerosol	—	No
9	OVA (1 mg)	OVA/alum i.p.	Aerosol	No
6	OVA (100 μg)	Aerosol	—	No
3	OVA (100 μg)	OVA/alum	Aerosol	Yes
3	OVA (100 μg)/IFA	Aerosol	—	Yes
3	OVA (100 μg)/IFA	OVA/alum	Aerosol	Yes
1	OVA (10 μg)	Aerosol	—	Yes
3	OVA (10 μg)	OVA/alum	Aerosol	Yes

Soluble OVA at doses of 100 μg or 1 mg did not prime for Th2 responses and AAD. Importantly, 1 mg OVA prevented subsequent priming and induction of AAD. In contrast, 100 μg OVA in IFA primed for Th2 responses and subsequent aerosol induced AAD. Interestingly, administration of 10 μg of soluble OVA also primed for a Th2 response and subsequent AAD.